Amgen Drug Sale Dwarfed By Denosumab Suspense
This article was originally published in The Pink Sheet Daily
Executive Summary
Sale, license of three drugs to Swedish firm happens ahead of key Phase III osteo results.
You may also be interested in...
FDA Advisory Panel Undecided On Fablyn’s Mortality Trend
Reproductive Health Drugs advisory panel concludes the benefits of Pfizer’s lasofoxifene outweigh its risks in specific populations of women with postmenopausal osteoporosis.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.